Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

PP405 is being discussed for hair regrowth, with mixed opinions on its effectiveness and legitimacy. Some users report early signs of regrowth, while others are skeptical about its authenticity and results.

PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

The conversation is about finding alternatives to Nizoral for dandruff treatment. Suggestions include coconut oil, Regenepure DR, apple cider vinegar, Mg217, and zinc pyrithione-based shampoos.

Breezula shows promising results for hair loss, with one trial showing a 539% improvement and another 168%, but lacks combination data with treatments like minoxidil or dutasteride. Its mechanism differs from finasteride, potentially offering fewer side effects by blocking receptors locally at the follicle.

PP405 is expected to work for hair regrowth by reactivating stem cells in hair follicles, with FDA approval anticipated in 2027-28. Users express both optimism and skepticism about its effectiveness and the lengthy approval process.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

A product called HairMDL includes Minoxidil, Dutasteride, Latanoprost, caffeine, Tretinoin, and Triamcinolone. Users are curious about its effectiveness and safety, particularly regarding the topical steroid Triamcinolone.

A user is creating a home topical solution for hair loss using zinc, essential oils, and caffeine, aiming for a 0.001% caffeine concentration. They also use topical finasteride and are considering other treatments like low-level laser therapy, while discussing the effectiveness of various hair loss treatments with others.

The conversation is about using Bimatoprost for hair growth, with concerns about potential side effects like eye color change and fat atrophy. Users discuss combining it with other treatments like Minoxidil and Finasteride, and sourcing Bimatoprost in bulk.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

Oral minoxidil (Loniten) and topical spironolactone are discussed for hair loss treatment, with mixed results and potential side effects like unwanted body hair. Finasteride is suggested as a better alternative for men, and dosages for oral minoxidil range from 2.5 mg to 5 mg daily.

A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

The user is seeking a gentle, fragrance-free daily shampoo for a sensitive scalp with mild psoriasis, considering options like Cleure, CeraVe, and Vanicream. They are also contemplating using Nizoral once a week despite concerns about its harshness.

The user is using a topical solution with finasteride, minoxidil, and tretinoin and is considering adding GHK-Cu to enhance hair growth and quality. Another user suggests diluting GHK-Cu and storing it in a smaller, refrigerated bottle.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Alcohol-free minoxidil options in Europe, particularly from a German pharmacy, are recommended for those with seborrheic dermatitis. Users suggest alternatives like Alopexy and Doppelherz foam, and emphasize avoiding propylene glycol and alcohol to reduce irritation.

The conversation is about a person's hair loss treatment regimen, which includes Minoxidil, low-dose Finasteride, Pyrilutamide, weekly use of a derma roller, and hair loss shampoo. They chose these treatments to minimize systemic effects and plan to share their results for others' benefit.

A user started a hair loss treatment 6 weeks ago using oral finasteride, minoxidil, biotin, vitamins B5, B6, and C, along with a topical serum containing batana, rosemary, castor oils, rice water, and more biotin. They are hoping to see progress by June-July.

PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.

The conversation discusses sourcing topical dutasteride for hair loss treatment, with mentions of Dr. Mwamba's products and Farmacia Prati as potential suppliers. Additional treatments like topical tocotrienols and botox are suggested as extensions to the regimen.

Buffering tretinoin with a moisturizer before applying minoxidil may help with itchy dandruff. Exfoliating the scalp with fingertips and using olive oil or conditioner can remove product buildup.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

The conversation discusses potential hair loss treatments, including clascoterone, GT20029, ET-02, VDPHL01, and PP405, with hopes for new options by 2028. Current treatments like minoxidil and finasteride are expected to remain effective, with clascoterone and VDPHL01 as promising alternatives.